Positioning no disclosures inside 60 days, left as found
Options no verdict drawn today, left as found
Ethical does not pass the values gate
Price30.42 USD
Fair value39.00
Ethical score10.0/100
RatingAVOID
Our investment reviews on this name
2026-10-02Read Markdown30.42+0.0% to today
2026-09-02Read Accumulation32.02-5.0% to today
2026-08-03Read Markup29.43+3.4% to today ✓
2026-07-02Read Accumulation27.35+11.2% to today ✓
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Invesco holds its Markdown at $30.42. The statistical read favours the sellers, held for 194 days.
As held on the ledger · 2026-09-29
Phase
Markdown · caution
Quantitative state
The statistical read favours the sellers, held for 194 days
Price at the screen
$30.42
Valuation
N/A trailing · 9.33 forward price to earnings
Values screen
FAIL· score 10.0
Beta
1.61
The Workings
Five Screens, Shown in Full
Does not pass. Business activity screen
Test
Figure
Limit
What it means
Status
Business activity
Excluded
Core business clean
Business activity: Financials sector
Fail
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
Invesco does not clear the screen at the business-activity stage. It operates in conventional financial services, which the screen treats as interest-based, so the financial ratios are not the deciding factor here.
Read as at 2026-10-04. It updates when the underlying figures move, and past reads are kept below.
The Conscience Overlay
Conscience flag · Palestinian BDS National Committee
The quantitative screen above is arithmetic. Separately, community boycott lists cite this company: Documented on Palestinian BDS National Committee — category: Institutional Pressure / Financial. The desk records that flag here without folding it into the verdict: the screen measures the balance sheet, the overlay informs the conscience, and they are different judgements that belong to different owners. The second one is yours.
What the Numbers Say It Is Worth
The Fair Value Range
Our framework reads AVOID: it trades at roughly a 28% discount to our $39.00 fair value, weak competitive moat, 20.50% revenue growth.
Fair value range in USD, drawn from the 2026-09-29 screen. The gold marker is the market price at the same screen. A 28.2% margin of safety to the base estimate.
Third-party analyst targets: 13 covering, consensus Buy. The average target sits +12% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-09-29 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Asset managers hit their own ethical wall
Picture a fund house that takes client money yet trips its own business activity screen. Invesco lands in that spot, so we pass despite a forward P/E of 9.3x and revenue growth of 14 percent. The ethical failure overrides any surface appeal.
Numbers tell the same story. Profit margin sits at minus 4 percent, return on equity at minus 2 percent, and the moat is weak. Analysts may cluster around a 31 dollar target, yet the firm shows no durable edge that justifies stepping past the screen.
Asset management earnings swing with markets and flows. A low multiple on weak returns often signals a cyclical trap rather than value. Analysis, not advice.
The risks · The things to watch: it already moves more than the market on an average day.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
IVZ trades on a US exchange. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-10-02Markdown · changed$30.42-5.0%Entry 6
The framework has shifted from accumulation to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 5.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 14% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 91%. Our forward projection puts the odds of a 10% gain over the next month near 30%. The street (11 analysts) rates it buy, with a mean price target of $29.
The framework has shifted from markup to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 8.8% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 14% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 91%. Our forward projection puts the odds of a 10% gain over the next month near 30%. The street (11 analysts) rates it buy, with a mean price target of $29.
2026-08-03Markup · changed$29.43+7.6%Entry 4
The framework has shifted from accumulation to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 7.6% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 14% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 91%. Our forward projection puts the odds of a 10% gain over the next month near 30%. The street (11 analysts) rates it buy, with a mean price target of $29.
2026-07-18Accumulation$27.35+0.0%Entry 3
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 14% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 91%. Our forward projection puts the odds of a 10% gain over the next month near 30%. The street (11 analysts) rates it buy, with a mean price target of $29.
2026-07-03Accumulation$27.35+0.0%Entry 2
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns.
2026-07-02Accumulation$27.35Entry 1
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.